Arterial atherosclerosis in patients with chronic kidney disease and its relationship with serum and tissue

Iranian Journal of Kidney Diseases

Volumn 3, Issue 4, 2009, Pages 203-209

  Noshad, Hamid ^a   Argani, Hassan ^b   Nezami, Nariman ^c   Ghojazadeh, Morteza ^c   Zomorrodi, Afshar ^c   Bohlouli, Abolfazl ^c   Bonyadi, Mohammad Reza ^c   Fakhrjou, Ashraf ^c   Ghorbanihaghjo, Amir ^c   Gharedaghi, Abasat ^c   Javadzadegan, Hassan ^a   Sadreddini, Shahram ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Atherosclerosis; Chronic kidney disease; Endothelin 1

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; ENDOTHELIN 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTERIOVENOUS FISTULA; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; KIDNEY DONOR; LIPID BLOOD LEVEL; MALE; PROTEIN BLOOD LEVEL; RENAL ARTERY; TISSUE LEVEL;

ADULT; ARTERIOVENOUS SHUNT, SURGICAL; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; COHORT STUDIES; ENDOTHELIN-1; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RISK FACTORS;

EID: 73949134487     PISSN: 17358582     EISSN: 17358604     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Goch A, Banach M, Mikhailidis DP, Rysz J, Goch JH. Endothelial dysfunction in patients with noncomplicated and complicated hypertension. Clin Exp Hypertens. 2009;31:20-30.
2. Anggrahini DW, Emoto N, Nakayama K, et al. Vascular endothelial cell-derived endothelin-1 mediates vascular inflammation and neointima formation following blood flow cessation. Cardiovasc Res. 2009;82:143-51.
3. Little PJ, Ivey ME, Osman N. Endothelin-1 actions on vascular smooth muscle cell functions as a target for the prevention of atherosclerosis. Curr Vasc Pharmacol. 2008;6:195-203.
4. Rudijanto A. The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. Acta Med Indones. 2007;39:86-93.
5. Shah R. Endothelins in health and disease. Eur J Intern Med. 2007;18:272-82.
6. Davenport AP, Maguire JJ. Endothelin. Handb Exp Pharmacol. 2006;(176 Pt 1):295-329.
7. Ishihata A, Katano Y. Role of angiotensin II and endothelin-1 receptors in aging-related functional changes in rat cardiovascular system. Ann N Y Acad Sci. 2006;1067:173-81.
8. McCarter SD, Lai PF, Suen RS, Stewart DJ. Regulation of endothelin-1 by angiopoietin-1: implications for inflammation. Exp Biol Med (Maywood). 2006;231:985-91.
9. Jesmin S, Zaedi S, Maeda S, et al. Endothelin antagonism suppresses plasma and cardiac endothelin-1 levels in SHRSPs at the typical hypertensive stage. Exp Biol Med (Maywood). 2006;231:919-24.
10. Spieker LE, Luscher TF. Protection of endothelial function. Handb Exp Pharmacol. 2005619-44.
11. Dhaun N, Goddard J, Webb DJ. The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol. 2006;17:943-55.
12. Browatzki M, Pfeiffer CA, Schmidt J, Kranzhofer R. Endothelin-1 induces CD40 but not IL-6 in human monocytes via the proinflammatory transcription factor NF-kappaB. Eur J Med Res. 2005;10:197-201.
13. Stefanidis I, Wurth P, Mertens PR, et al. Plasma endothelin-1 in hemodialysis treatment - the influence of hypertension. J Cardiovasc Pharmacol. 2004;44 Suppl 1:S43-8.
14. Teplyakov AI. Endothelin-1 involved in systemic cytokine network inflammatory response at atherosclerosis. J Cardiovasc Pharmacol. 2004;44 Suppl 1:S274-5.
15. Mawatari K, Kakui S, Harada N, et al. Endothelin-1(1-31) levels are increased in atherosclerotic lesions of the thoracic aorta of hypercholesterolemic hamsters. Atherosclerosis. 2004;175:203-12.
16. Radeau T, Lebel M, Houde I, et al. Endothelin-1 levels and cardiovascular risk factors in renal transplant patients. Clin Biochem. 2004;37:1072-8.
17. Ihling C, Bohrmann B, Schaefer HE, Technau-Ihling K, Loeffler BM. Endothelin-1 and endothelin converting enzyme-1 in human atherosclerosis - novel targets for pharmacotherapy in atherosclerosis. Curr Vasc Pharmacol. 2004;2:249-58.
18. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol. 1999;34:631-8.
19. Nohria A, Garrett L, Johnson W, Kinlay S, Ganz P, Creager MA. Endothelin-1 and vascular tone in subjects with atherogenic risk factors. Hypertension. 2003;42:43-8.
20. Spieker LE, Noll G, Luscher TF. Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders. Am J Cardiovasc Drugs. 2001;1:293-303.
21. Li L, Chu Y, Fink GD, Engelhardt JF, Heistad DD, Chen AF. Endothelin-1 stimulates arterial VCAM-1 expression via NADPH oxidase-derived superoxide in mineralocorticoid hypertension. Hypertension. 2003;42:997-1003.
22. Amann K, Tyralla K, Gross ML, Eifert T, Adamczak M, Ritz E. Special characteristics of atherosclerosis in chronic renal failure. Clin Nephrol. 2003;60 Suppl 1:S13-21.
23. Lariviere R, Lebel M. Endothelin-1 in chronic renal failure and hypertension. Can J Physiol Pharmacol. 2003;81:607-21.
24. Bousette N, Giaid A. Endothelin-1 in atherosclerosis and other vasculopathies. Can J Physiol Pharmacol. 2003;81:578-87.
25. Touyz RM, Schiffrin EL. Role of endothelin in human hypertension. Can J Physiol Pharmacol. 2003;81:533-41.
26. Doggrell SA. The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system. Expert Opin Investig Drugs. 2002;11:1537-52.
27. Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation. 2002;106:1783-7.
28. Wiley KE, Davenport AP. Comparison of the effects of atherosclerosis and nitrate therapy on responses to nitric oxide and endothelin-1 in human arteries in vitro. Clin Sci (Lond). 2002;103 Suppl 48:124S-7S.
29. Bohm F, Ahlborg G, Johansson BL, Hansson LO, Pernow J. Combined endothelin receptor blockade evokes enhanced vasodilatation in patients with atherosclerosis. Arterioscler Thromb Vasc Biol. 2002;22:674-9.
30. Bohm F, Ahlborg G, Pernow J. Endothelin-1 inhibits endothelium-dependent vasodilatation in the human forearm: reversal by ETA receptor blockade in patients with atherosclerosis. Clin Sci (Lond). 2002;102:321-7.
31. Dashwood MR, Tsui JC. Endothelin-1 and atherosclerosis: potential complications associated with endothelinreceptor blockade. Atherosclerosis. 2002;160:297-304.
32. d'Uscio LV, Barton M, Shaw S, Luscher TF. Chronic ET(A) receptor blockade prevents endothelial dysfunction of small arteries in apolipoprotein E-deficient mice. Cardiovasc Res. 2002;53:487-95.
33. Ergul A. Endothelin-1 and endothelin receptor antagonists as potential cardiovascular therapeutic agents. Pharmacotherapy. 2002;22:54-65.
34. Minami S, Yamano S, Yamamoto Y, et al. Associations of plasma endothelin concentration with carotid atherosclerosis and asymptomatic cerebrovascular lesions in patients with essential hypertension. Hypertens Res. 2001;24:663-70.
35. Bohm F, Johansson BL, Hedin U, Alving K, Pernow J. Enhanced vasoconstrictor effect of big endothelin-1 in patients with atherosclerosis: relation to conversion to endothelin-1. Atherosclerosis. 2002;160:215-22.
36. Haug C, Schmid-Kotsas A, Zorn U, et al. Endothelin-1 synthesis and endothelin B receptor expression in human coronary artery smooth muscle cells and monocytederived macrophages is up-regulated by low density lipoproteins. J Mol Cell Cardiol. 2001;33:1701-12.
37. Barton M, Kiowski W. The therapeutic potential of endothelin receptor antagonists in cardiovascular disease. Curr Hypertens Rep. 2001;3:322-30.